Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)

Summary

In total 20 subjects will be enrolled at one participating site -UMC Ljubljana. The 20 subjects will be treated with placebo and NBMI 300 mg in a cross-over design. In case of subject drop-outs, additional subjects may be enrolled as decided by the Sponsor, to allow for expected number of evaluable subjects in each group.

Timeline

Start

2019-09-16

Primary completion

2020-07-30

Completion

2021-06-30

Drugs

Indications